Every peptide, ranked by documented risk

The same 89 compounds ordered the other way up: by how much harm is documented, how little oversight there is of what ends up in the vial, and how much is simply unknown because nobody has run the study. It is the table the evidence leaderboard needs beside it.

Compounds ranked: 89
Research-use-only material: 25
Highest risk score: 97/100
Widest risk-evidence gap: +82

A low position here does not mean safe. This scores what has been documented. A compound nobody has studied has little documented harm and still scores points for exactly that reason — but an absence of reports is not a safety record, and the score cannot capture what has never been looked for. Read the safety page for the risks that cross every compound in the library.

One column does most of the work: whether anybody is checking what is in the vial. Independent testing of grey-market peptides has repeatedly found products underdosed, overdosed, degraded, contaminated or simply a different compound than the label claims — a hazard that exists whatever the molecule itself does, and one that no amount of mechanism can offset.

#	Compound	Status	Evidenceout of 100	Riskout of 100	Gaprisk − evidence	Why it sits here
1	BPC-157: 15 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 1 of 5 BPC-157 Healing & Tissue Repair · Body Protection Compound 157	Research Use Only	15	97	+82	Research Use Only. No benefit claim on strong human evidence. 7 serious or common risks.
1	MOTS-c: 16 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 1 of 5 MOTS-c Longevity & Mitochondrial · Mitochondrial ORF of the 12S rRNA type-c	Research Use Only	15	97	+82	Research Use Only. No benefit claim on strong human evidence. 5 serious or common risks.
3	Cartalax: 3 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 1 of 5 Cartalax Healing & Tissue Repair · AED	Research Use Only	15	95	+80	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
3	IGF-1 LR3: 83 amino acids (from the sequence record), disulfide bridge · Growth Hormone Axis · evidence 1 of 5 IGF-1 LR3 Growth Hormone Axis · Long R3 IGF-1	Research Use Only	15	95	+80	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
3	PE-22-28: 7 amino acids (from the sequence record) · Cognitive & Neurological · evidence 1 of 5 PE-22-28 Cognitive & Neurological · PE 22-28	Research Use Only	15	95	+80	Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks.
3	PTD-DBM: 25 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 1 of 5 PTD-DBM Healing & Tissue Repair · Protein transduction domain-Dishevelled binding motif	Research Use Only	15	95	+80	Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks.
7	CJC-1295: 30 amino acids (from the sequence record) · Growth Hormone Axis · evidence 2 of 5 CJC-1295 Growth Hormone Axis · Modified GRF (1-29)	Research Use Only	30	91	+61	Research Use Only. No benefit claim on strong human evidence. 5 serious or common risks.
7	Ipamorelin: 5 amino acids (from the sequence record) · Growth Hormone Axis · evidence 2 of 5 Ipamorelin Growth Hormone Axis · NNC 26-0161	Research Use Only	30	91	+61	Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks.
7	Livagen: 4 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 2 of 5 Livagen Longevity & Mitochondrial · KEDA	Research Use Only	30	91	+61	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
7	TB-500 / Thymosin Beta-4: 43 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 2 of 5 TB-500 / Thymosin Beta-4 Healing & Tissue Repair · TB4	Research Use Only	30	91	+61	Research Use Only. No benefit claim on strong human evidence. 7 serious or common risks.
11	5-Amino-1MQ: structure not stated · Metabolic & Weight · evidence 1 of 5 5-Amino-1MQ Metabolic & Weight · 5-amino-1-methylquinolinium	Not a Peptide	15	89	+74	Not a Peptide. No benefit claim on strong human evidence. 4 serious or common risks.
11	Dihexa: 3 amino acids (from the sequence record), fatty-acid chain · Cognitive & Neurological · evidence 1 of 5 Dihexa Cognitive & Neurological · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide	Research Use Only	15	89	+74	Research Use Only. No benefit claim on strong human evidence. 5 serious or common risks.
11	Follistatin-344: 315 amino acids (from the sequence record), disulfide bridge · Bone, Muscle & Other · evidence 1 of 5 Follistatin-344 Bone, Muscle & Other · FST-344	Research Use Only	15	89	+74	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
11	GDF-11: 218 amino acids (from the sequence record), disulfide bridge · Longevity & Mitochondrial · evidence 1 of 5 GDF-11 Longevity & Mitochondrial · Growth Differentiation Factor 11	Research Use Only	15	89	+74	Research Use Only. No benefit claim on strong human evidence. 6 serious or common risks.
11	Melanotan II: 7 amino acids (from the sequence record), cyclic · Sexual Health & Melanocortin · evidence 1 of 5 Melanotan II Sexual Health & Melanocortin · MT-II	Research Use Only	15	89	+74	Research Use Only. No benefit claim on strong human evidence. 6 serious or common risks.
16	NAD+ (Nicotinamide Adenine Dinucleotide): structure not stated · Longevity & Mitochondrial · evidence 2 of 5 NAD+ (Nicotinamide Adenine Dinucleotide) Longevity & Mitochondrial · NAD	Not a Peptide	32	83	+51	Not a Peptide. 1 benefit claim on strong human evidence. 4 serious or common risks.
17	Adipotide: 25 amino acids (from the sequence record) · Bone, Muscle & Other · evidence 1 of 5 Adipotide Bone, Muscle & Other · FTPP	Research Use Only	15	82	+67	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
17	FOXO4-DRI: 46 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 1 of 5 FOXO4-DRI Longevity & Mitochondrial · FOXO4-p53 interfering peptide	Research Use Only	15	82	+67	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
17	Pentadeca Arginate (PDA): 15 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 1 of 5 Pentadeca Arginate (PDA) Healing & Tissue Repair · PDA	Research Use Only	15	82	+67	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
20	Epitalon: 4 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 2 of 5 Epitalon Longevity & Mitochondrial · Epithalon	Research Use Only	30	81	+51	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
20	LL-37: 37 amino acids (from the sequence record) · Antimicrobial & Antibiotic · evidence 2 of 5 LL-37 Antimicrobial & Antibiotic · Cathelicidin	Research Use Only	30	81	+51	Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks.
22	AHK-Cu: 3 amino acids (from the sequence record), metal centre · Skin & Cosmetic · evidence 1 of 5 AHK-Cu Skin & Cosmetic · Copper tripeptide-3	Cosmetic Ingredient	17	78	+61	Cosmetic Ingredient. No benefit claim on strong human evidence. 4 serious or common risks.
23	MK-677 (Ibutamoren): peptidomimetic / small molecule · Growth Hormone Axis · evidence 3 of 5 MK-677 (Ibutamoren) Growth Hormone Axis · Ibutamoren	Not a Peptide	49	77	+28	Not a Peptide. 2 benefit claims on strong human evidence. 4 serious or common risks.
24	Hexarelin: 6 amino acids (from the sequence record) · Growth Hormone Axis · evidence 2 of 5 Hexarelin Growth Hormone Axis · Examorelin	Research Use Only	30	76	+46	Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks.
25	Angiotensin (1-7): 7 amino acids (from the sequence record) · Cardiac & Vascular · evidence 3 of 5 Angiotensin (1-7) Cardiac & Vascular · Ang-(1-7)	In Clinical Trials	51	75	+24	In Clinical Trials. 1 benefit claim on strong human evidence. 3 serious or common risks.
25	Humanin: 24 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 1 of 5 Humanin Longevity & Mitochondrial · HN	Research Use Only	15	75	+60	Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks.
27	DSIP: 9 amino acids (from the sequence record) · Bone, Muscle & Other · evidence 1 of 5 DSIP Bone, Muscle & Other · Delta Sleep-Inducing Peptide	Research Use Only	15	73	+58	Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks.
28	GHRP-6: 6 amino acids (from the sequence record) · Growth Hormone Axis · evidence 2 of 5 GHRP-6 Growth Hormone Axis · Growth Hormone Releasing Hexapeptide	Research Use Only	30	69	+39	Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks.
29	KPV: 3 amino acids (from the sequence record) · Immune & Anti-inflammatory · evidence 1 of 5 KPV Immune & Anti-inflammatory · Lysine-Proline-Valine	Research Use Only	15	68	+53	Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks.
30	GHK-Cu: 3 amino acids (from the sequence record), metal centre · Skin & Cosmetic · evidence 3 of 5 GHK-Cu Skin & Cosmetic · Copper tripeptide-1	Cosmetic Ingredient	47	66	+19	Cosmetic Ingredient. No benefit claim on strong human evidence. 3 serious or common risks.
31	Thymalin: a mixture, not one molecule · Immune & Anti-inflammatory · evidence 2 of 5 Thymalin Immune & Anti-inflammatory · Thymus extract peptide complex	Limited Approval	37	65	+28	Limited Approval. No benefit claim on strong human evidence. 4 serious or common risks.
32	Retatrutide: 39 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 3 of 5 Retatrutide Metabolic & Weight · LY3437943	In Clinical Trials	49	64	+15	In Clinical Trials. No benefit claim on strong human evidence. 3 serious or common risks.
33	Desmopressin: 9 amino acids (from the sequence record), disulfide bridge · Cardiac & Vascular · evidence 5 of 5 Desmopressin Cardiac & Vascular · DDAVP	FDA Approved	97	63	-34	FDA Approved. 5 benefit claims on strong human evidence. 3 serious or common risks.
33	Semaglutide: 31 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 5 of 5 Semaglutide Metabolic & Weight · Ozempic	FDA Approved	98	63	-35	FDA Approved. 4 benefit claims on strong human evidence. 3 serious or common risks.
33	Somatropin (recombinant hGH): 191 amino acids (from the sequence record), disulfide bridge · Growth Hormone Axis · evidence 5 of 5 Somatropin (recombinant hGH) Growth Hormone Axis · rhGH	FDA Approved	93	63	-30	FDA Approved. 3 benefit claims on strong human evidence. 6 serious or common risks.
33	Tirzepatide: 39 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 5 of 5 Tirzepatide Metabolic & Weight · Mounjaro	FDA Approved	93	63	-30	FDA Approved. 3 benefit claims on strong human evidence. 3 serious or common risks.
33	Vancomycin: 7 amino acids (from the sequence record), cyclic · Antimicrobial & Antibiotic · evidence 5 of 5 Vancomycin Antimicrobial & Antibiotic · Vancocin	FDA Approved	95	63	-32	FDA Approved. 4 benefit claims on strong human evidence. 3 serious or common risks.
38	Colistin (Polymyxin E): 10 amino acids (from the sequence record), cyclic, fatty-acid chain · Antimicrobial & Antibiotic · evidence 4 of 5 Colistin (Polymyxin E) Antimicrobial & Antibiotic · Colistimethate sodium	FDA Approved	74	61	-13	FDA Approved. 1 benefit claim on strong human evidence. 4 serious or common risks.
38	Selank: 7 amino acids (from the sequence record) · Cognitive & Neurological · evidence 2 of 5 Selank Cognitive & Neurological · TP-7	Limited Approval	37	61	+24	Limited Approval. No benefit claim on strong human evidence. 3 serious or common risks.
38	Semax: 7 amino acids (from the sequence record) · Cognitive & Neurological · evidence 2 of 5 Semax Cognitive & Neurological · ACTH (4-10) Pro-Gly-Pro	Limited Approval	37	61	+24	Limited Approval. No benefit claim on strong human evidence. 3 serious or common risks.
41	AOD-9604: 16 amino acids (from the sequence record), disulfide bridge · Metabolic & Weight · evidence 2 of 5 AOD-9604 Metabolic & Weight · hGH fragment 176-191	Research Use Only	30	59	+29	Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks.
41	Ciclosporin (Cyclosporine A): 11 amino acids (from the sequence record), cyclic · Ophthalmic · evidence 5 of 5 Ciclosporin (Cyclosporine A) Ophthalmic · Restasis	FDA Approved	100	59	-41	FDA Approved. 5 benefit claims on strong human evidence. 3 serious or common risks.
41	Leuprolide: 9 amino acids (from the sequence record) · Hormonal & Reproductive · evidence 5 of 5 Leuprolide Hormonal & Reproductive · Lupron	FDA Approved	95	59	-36	FDA Approved. 4 benefit claims on strong human evidence. 4 serious or common risks.
41	Oxytocin: 9 amino acids (from the sequence record), disulfide bridge · Hormonal & Reproductive · evidence 5 of 5 Oxytocin Hormonal & Reproductive · Pitocin	FDA Approved	96	59	-37	FDA Approved. 3 benefit claims on strong human evidence. 3 serious or common risks.
45	Kisspeptin-10: 10 amino acids (from the sequence record) · Hormonal & Reproductive · evidence 3 of 5 Kisspeptin-10 Hormonal & Reproductive · KP-10	In Clinical Trials	49	58	+9	In Clinical Trials. No benefit claim on strong human evidence. 3 serious or common risks.
46	Cerebrolysin: a mixture, not one molecule · Cognitive & Neurological · evidence 3 of 5 Cerebrolysin Cognitive & Neurological · FPF-1070	Limited Approval	52	57	+5	Limited Approval. No benefit claim on strong human evidence. 3 serious or common risks.
46	Daptomycin: 13 amino acids (from the sequence record), cyclic, fatty-acid chain · Antimicrobial & Antibiotic · evidence 5 of 5 Daptomycin Antimicrobial & Antibiotic · Cubicin	FDA Approved	93	57	-36	FDA Approved. 3 benefit claims on strong human evidence. 3 serious or common risks.
46	Glutathione: 3 amino acids (from the sequence record) · Bone, Muscle & Other · evidence 3 of 5 Glutathione Bone, Muscle & Other · GSH	Limited Approval	56	57	+1	Limited Approval. 2 benefit claims on strong human evidence. 3 serious or common risks.
46	Human Chorionic Gonadotropin (hCG): 237 amino acids (from the sequence record), disulfide bridge · Hormonal & Reproductive · evidence 5 of 5 Human Chorionic Gonadotropin (hCG) Hormonal & Reproductive · Pregnyl	FDA Approved	95	57	-38	FDA Approved. 4 benefit claims on strong human evidence. 3 serious or common risks.
50	Noopept: 2 amino acids (from the sequence record) · Cognitive & Neurological · evidence 2 of 5 Noopept Cognitive & Neurological · N-phenylacetyl-L-prolylglycine ethyl ester	Limited Approval	37	56	+19	Limited Approval. No benefit claim on strong human evidence. 2 serious or common risks.
51	Survodutide: 29 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 3 of 5 Survodutide Metabolic & Weight · BI 456906	In Clinical Trials	49	55	+6	In Clinical Trials. No benefit claim on strong human evidence. 2 serious or common risks.
52	Teduglutide: 33 amino acids (from the sequence record) · Gut & Gastrointestinal · evidence 5 of 5 Teduglutide Gut & Gastrointestinal · Gattex	FDA Approved	93	52	-41	FDA Approved. 3 benefit claims on strong human evidence. 3 serious or common risks.
53	Plecanatide: 16 amino acids (from the sequence record), disulfide bridge · Gut & Gastrointestinal · evidence 4 of 5 Plecanatide Gut & Gastrointestinal · Trulance	FDA Approved	76	50	-26	FDA Approved. 2 benefit claims on strong human evidence. 3 serious or common risks.
54	Orforglipron: peptidomimetic / small molecule · Metabolic & Weight · evidence 4 of 5 Orforglipron Metabolic & Weight · LY3502970	In Clinical Trials	70	49	-21	In Clinical Trials. 3 benefit claims on strong human evidence. 2 serious or common risks.
54	PT-141 (Bremelanotide): 7 amino acids (from the sequence record), cyclic · Sexual Health & Melanocortin · evidence 5 of 5 PT-141 (Bremelanotide) Sexual Health & Melanocortin · Bremelanotide	FDA Approved	93	49	-44	FDA Approved. 3 benefit claims on strong human evidence. 2 serious or common risks.
54	Teriparatide: 34 amino acids (from the sequence record) · Bone, Muscle & Other · evidence 5 of 5 Teriparatide Bone, Muscle & Other · Forteo	FDA Approved	98	49	-49	FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks.
57	ARA-290 (Cibinetide): 11 amino acids (from the sequence record) · Healing & Tissue Repair · evidence 3 of 5 ARA-290 (Cibinetide) Healing & Tissue Repair · Cibinetide	In Clinical Trials	51	48	-3	In Clinical Trials. 1 benefit claim on strong human evidence. 2 serious or common risks.
57	Biotinoyl Tripeptide-1 (Biotinyl-GHK): 3 amino acids (from the sequence record) · Skin & Cosmetic · evidence 2 of 5 Biotinoyl Tripeptide-1 (Biotinyl-GHK) Skin & Cosmetic · Biotinyl-GHK	Cosmetic Ingredient	32	48	+16	Cosmetic Ingredient. No benefit claim on strong human evidence.
59	Acetyl Tetrapeptide-3: 4 amino acids (from the sequence record) · Skin & Cosmetic · evidence 2 of 5 Acetyl Tetrapeptide-3 Skin & Cosmetic · Ac-KGHK-NH2	Cosmetic Ingredient	32	47	+15	Cosmetic Ingredient. No benefit claim on strong human evidence. 1 serious or common risk.
59	Exenatide: 39 amino acids (from the sequence record) · Metabolic & Weight · evidence 5 of 5 Exenatide Metabolic & Weight · Byetta	FDA Approved	95	47	-48	FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks.
59	GHRP-2: 6 amino acids (from the sequence record) · Growth Hormone Axis · evidence 3 of 5 GHRP-2 Growth Hormone Axis · Pralmorelin	Limited Approval	54	47	-7	Limited Approval. 1 benefit claim on strong human evidence. 2 serious or common risks.
59	Gonadorelin: 10 amino acids (from the sequence record) · Hormonal & Reproductive · evidence 3 of 5 Gonadorelin Hormonal & Reproductive · GnRH	Limited Approval	56	47	-9	Limited Approval. 2 benefit claims on strong human evidence. 2 serious or common risks.
59	Linaclotide: 14 amino acids (from the sequence record), disulfide bridge · Gut & Gastrointestinal · evidence 5 of 5 Linaclotide Gut & Gastrointestinal · Linzess	FDA Approved	95	47	-48	FDA Approved. 4 benefit claims on strong human evidence. 3 serious or common risks.
64	Cagrilintide: 37 amino acids (from the sequence record), fatty-acid chain, disulfide bridge · Metabolic & Weight · evidence 3 of 5 Cagrilintide Metabolic & Weight · CagriSema (with semaglutide)	In Clinical Trials	49	46	-3	In Clinical Trials. No benefit claim on strong human evidence. 2 serious or common risks.
64	Thymosin Alpha-1: 28 amino acids (from the sequence record) · Immune & Anti-inflammatory · evidence 4 of 5 Thymosin Alpha-1 Immune & Anti-inflammatory · Tα1	Limited Approval	71	46	-25	Limited Approval. 2 benefit claims on strong human evidence. 2 serious or common risks.
66	Nesiritide: 32 amino acids (from the sequence record), disulfide bridge · Cardiac & Vascular · evidence 5 of 5 Nesiritide Cardiac & Vascular · Natrecor	FDA Approved	91	45	-46	FDA Approved. 2 benefit claims on strong human evidence. 2 serious or common risks.
67	GPIGS (Pentapeptide-20): 5 amino acids (from the sequence record) · Skin & Cosmetic · evidence 3 of 5 GPIGS (Pentapeptide-20) Skin & Cosmetic · Pentapeptide-20	Cosmetic Ingredient	47	44	-3	Cosmetic Ingredient. No benefit claim on strong human evidence. 1 serious or common risk.
68	Davunetide: 8 amino acids (from the sequence record) · Cognitive & Neurological · evidence 3 of 5 Davunetide Cognitive & Neurological · NAP	In Clinical Trials	51	43	-8	In Clinical Trials. 1 benefit claim on strong human evidence. 2 serious or common risks.
68	Sermorelin: 29 amino acids (from the sequence record) · Growth Hormone Axis · evidence 3 of 5 Sermorelin Growth Hormone Axis · GHRH (1-29)	Limited Approval	54	43	-11	Limited Approval. 1 benefit claim on strong human evidence. 1 serious or common risk.
68	Vasoactive Intestinal Peptide (VIP): 28 amino acids (from the sequence record) · Immune & Anti-inflammatory · evidence 2 of 5 Vasoactive Intestinal Peptide (VIP) Immune & Anti-inflammatory · Aviptadil	In Clinical Trials	34	43	+9	In Clinical Trials. No benefit claim on strong human evidence.
71	Mazdutide: 34 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 4 of 5 Mazdutide Metabolic & Weight · IBI362	Limited Approval	71	42	-29	Limited Approval. 2 benefit claims on strong human evidence. 1 serious or common risk.
71	Tesamorelin: 44 amino acids (from the sequence record), fatty-acid chain · Growth Hormone Axis · evidence 5 of 5 Tesamorelin Growth Hormone Axis · Egrifta	FDA Approved	89	42	-47	FDA Approved. 1 benefit claim on strong human evidence. 1 serious or common risk.
73	Dulaglutide: 550 amino acids (from the sequence record), disulfide bridge · Metabolic & Weight · evidence 5 of 5 Dulaglutide Metabolic & Weight · Trulicity	FDA Approved	91	40	-51	FDA Approved. 2 benefit claims on strong human evidence. 2 serious or common risks.
74	Liraglutide: 31 amino acids (from the sequence record), fatty-acid chain · Metabolic & Weight · evidence 5 of 5 Liraglutide Metabolic & Weight · Victoza	FDA Approved	98	39	-59	FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks.
74	Macimorelin: 3 amino acids (from the sequence record) · Growth Hormone Axis · evidence 5 of 5 Macimorelin Growth Hormone Axis · Macrilen	FDA Approved	93	39	-54	FDA Approved. 3 benefit claims on strong human evidence. 2 serious or common risks.
76	Elamipretide (SS-31): 4 amino acids (from the sequence record) · Longevity & Mitochondrial · evidence 4 of 5 Elamipretide (SS-31) Longevity & Mitochondrial · SS-31	FDA Approved	78	36	-42	FDA Approved. 3 benefit claims on strong human evidence. 2 serious or common risks.
76	Insulin: 51 amino acids (from the sequence record), disulfide bridge · Metabolic & Weight · evidence 5 of 5 Insulin Metabolic & Weight · Human insulin	FDA Approved	95	36	-59	FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks.
78	Lanreotide: 8 amino acids (from the sequence record), cyclic, disulfide bridge · Hormonal & Reproductive · evidence 5 of 5 Lanreotide Hormonal & Reproductive · Somatuline Depot	FDA Approved	96	34	-62	FDA Approved. 3 benefit claims on strong human evidence. 1 serious or common risk.
79	Larazotide Acetate: 8 amino acids (from the sequence record) · Gut & Gastrointestinal · evidence 3 of 5 Larazotide Acetate Gut & Gastrointestinal · AT-1001	In Clinical Trials	51	31	-20	In Clinical Trials. 1 benefit claim on strong human evidence. 1 serious or common risk.
79	Octreotide: 8 amino acids (from the sequence record), cyclic, disulfide bridge · Hormonal & Reproductive · evidence 5 of 5 Octreotide Hormonal & Reproductive · Sandostatin	FDA Approved	93	31	-62	FDA Approved. 3 benefit claims on strong human evidence. 1 serious or common risk.
81	Setmelanotide: 8 amino acids (from the sequence record), cyclic, disulfide bridge · Metabolic & Weight · evidence 5 of 5 Setmelanotide Metabolic & Weight · Imcivree	FDA Approved	93	30	-63	FDA Approved. 3 benefit claims on strong human evidence. 1 serious or common risk.
82	Abaloparatide: 34 amino acids (from the sequence record) · Bone, Muscle & Other · evidence 5 of 5 Abaloparatide Bone, Muscle & Other · Tymlos	FDA Approved	98	29	-69	FDA Approved. 4 benefit claims on strong human evidence. 1 serious or common risk.
83	Cenegermin: 118 amino acids (from the sequence record), disulfide bridge · Ophthalmic · evidence 5 of 5 Cenegermin Ophthalmic · Oxervate	FDA Approved	91	26	-65	FDA Approved. 2 benefit claims on strong human evidence.
83	SNAP-8 (Acetyl Octapeptide-3): 8 amino acids (from the sequence record) · Skin & Cosmetic · evidence 2 of 5 SNAP-8 (Acetyl Octapeptide-3) Skin & Cosmetic · Acetyl glutamyl heptapeptide-1	Cosmetic Ingredient	32	26	-6	Cosmetic Ingredient. No benefit claim on strong human evidence.
85	Glucagon: 29 amino acids (from the sequence record) · Metabolic & Weight · evidence 5 of 5 Glucagon Metabolic & Weight · GlucaGen	FDA Approved	93	24	-69	FDA Approved. 3 benefit claims on strong human evidence. 1 serious or common risk.
86	Palmitoyl Tripeptide-1: 3 amino acids (from the sequence record), fatty-acid chain · Skin & Cosmetic · evidence 3 of 5 Palmitoyl Tripeptide-1 Skin & Cosmetic · Pal-GHK	Cosmetic Ingredient	49	22	-27	Cosmetic Ingredient. 1 benefit claim on strong human evidence.
87	Argireline (Acetyl Hexapeptide-8): 6 amino acids (from the sequence record) · Skin & Cosmetic · evidence 3 of 5 Argireline (Acetyl Hexapeptide-8) Skin & Cosmetic · Acetyl hexapeptide-3	Cosmetic Ingredient	51	19	-32	Cosmetic Ingredient. 2 benefit claims on strong human evidence.
87	Matrixyl (Palmitoyl Pentapeptide-4): 5 amino acids (from the sequence record), fatty-acid chain · Skin & Cosmetic · evidence 3 of 5 Matrixyl (Palmitoyl Pentapeptide-4) Skin & Cosmetic · Pal-KTTKS	Cosmetic Ingredient	49	19	-30	Cosmetic Ingredient. 1 benefit claim on strong human evidence.
89	Afamelanotide: 13 amino acids (from the sequence record) · Sexual Health & Melanocortin · evidence 5 of 5 Afamelanotide Sexual Health & Melanocortin · Melanotan I	FDA Approved	95	16	-79	FDA Approved. 4 benefit claims on strong human evidence.

How this score is calculated

Documented harms	high 12 · moderate 5 · low 2 Each risk on the monograph, weighted by how serious or common it is. Capped, so a compound cannot rank high on a long tail of minor complaints.
Supply and oversight	Research Use Only 22 · Not a Peptide 14 · In Clinical Trials 12 · Limited Approval 6 · Cosmetic Ingredient 3 Whether anyone is checking what is in the vial. Grey-market research-use-only material is the largest single hazard on this site and is scored that way, separately from whatever the molecule does.
What is not known	up to 12 Twelve points where no human has been studied, six where the human evidence is preliminary. An absence of reported harm in an untested compound is not a safety record.
Documented interactions	2 points each, up to 8 Two points for each interaction the monograph lists, up to four.

The score is capped at one hundred. It is built from what each monograph documents, so it moves when the record moves — a compound whose first real safety study reports moves on its own. It is not a probability, it is not a dose-response, and it cannot be compared between people.

Where risk runs furthest ahead of evidence

Subtracting one score from the other gives the most useful number on this site: how far the documented downside of a compound outruns anything demonstrated about its upside. These ten have the widest gap in the library.

+82
BPC-157
Risk 97 against evidence 15. Research Use Only, evidence rated 1 of 5, with 7 serious or common risks documented.
+82
MOTS-c
Risk 97 against evidence 15. Research Use Only, evidence rated 1 of 5, with 5 serious or common risks documented.
+80
Cartalax
Risk 95 against evidence 15. Research Use Only, evidence rated 1 of 5, with 4 serious or common risks documented.
+80
IGF-1 LR3
Risk 95 against evidence 15. Research Use Only, evidence rated 1 of 5, with 4 serious or common risks documented.
+80
PE-22-28
Risk 95 against evidence 15. Research Use Only, evidence rated 1 of 5, with 3 serious or common risks documented.
+80
PTD-DBM
Risk 95 against evidence 15. Research Use Only, evidence rated 1 of 5, with 3 serious or common risks documented.
+74
5-Amino-1MQ
Risk 89 against evidence 15. Not a Peptide, evidence rated 1 of 5, with 4 serious or common risks documented.
+74
Dihexa
Risk 89 against evidence 15. Research Use Only, evidence rated 1 of 5, with 5 serious or common risks documented.
+74
Follistatin-344
Risk 89 against evidence 15. Research Use Only, evidence rated 1 of 5, with 4 serious or common risks documented.
+74
GDF-11
Risk 89 against evidence 15. Research Use Only, evidence rated 1 of 5, with 6 serious or common risks documented.

A positive gap is not a verdict, it is a ratio of what is known. Several compounds here may turn out to work; the point is that today nobody can say so. The other side of the table is the evidence leaderboard.